May 11, 2010

On May 8 in 2010, reviews of updated recent clinical trial results for the treatment of chronic hepatitis B, Sebivo has been announced at the Satellite Symposium in the KASL Spring Conference held in Daegu.

Stefan Zeuzem, Professor of the Department of Medicine at the J.W. Goethe University Hospital in Frankfurt, Germany announced the efficacy, predictability and HBeAg seroconversion of Sebivo(Telbivudie) in CHB ?evidence from clinical trials. According to the results of the GLOBE study on telbivudine compared to lamivudine, undetectable serum HBV DNA at Week 24 was the strongest significant predictor of week 104 outcomes in HBeAg-positive pts. In efficacy with telbivudine at 4 years, PCR-negativity and ALT normalization were high with respectively 76%, 87%. But in the pts group achieved PCR-negativity at Week 24 of the patients treated with telbivudine, PCR-negativity and ALT normalization were higher with repectively 88%, 89%.

In Sustained HBeAg seroconversion, cumulative HBeAg seroconversion rate over 4 Years of telbivudine was 54% and in telbivudine-treated pts achieved PCR-negativity at Week 24, the rate reached surprising 66%. As the result of following up the 61 pts who discontinued due to efficacy during GLOBE and 015, HBeAg seroconversion is durable in 82% of patients after more than 2 yrs. And also HBeAg seroconversion timing is important. Earlier HBeAg seroconversion is associated with reduced risk of cirrhosis.

With the importance of HBeAg seroconversion in the treatment of chronic hepatitis B, Hwang Seong-Gyu, Professor of Department of Internal Medicine, CHA University emphasizes that HBeAg seroconversion is very meaningful to pts because it may lead to treatment cessation. In addition, as a result of animal testing, Th1 Cytokine levels is higher in telbivudine-treated CHB pts with complete response and a positive correlation exists between Th1-type cytokine level and reduction in serum HBV DNA in telbivudine-treated patients.